Sign In
Buy NTLA
$14.75
+1.73 (+13.29%)
At Close: Jun 04, 2026
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
11:15am, Thursday, 01'st Aug 2024
Ark Invest bought shares of AMD, Pinterest, and Intellia Therapeutics on Wednesday. AMD saw its AI chips sales skyrocket, even as the balance of its business is reeling.
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates
07:30am, Thursday, 01'st Aug 2024
CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
CAMBRIDGE, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Wednesday, 24'th Jul 2024
CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
7 Biotech Stocks to Keep on Your Clinical Radar
02:57pm, Tuesday, 23'rd Jul 2024
Initially, I had every intention to write a cookie-cutter assessment of intriguing biotech stocks; that is, I wanted to say that enterprises within this specialized healthcare field will always be rel
3 Gene Editing Stocks That Could Grow Your Wealth
01:30pm, Wednesday, 17'th Jul 2024
Gene editing stocks are often biopharmaceutical companies. At these firms, scientists use technology to change the DNA of organisms such as plants, bacteria and animals.
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
11:30am, Wednesday, 17'th Jul 2024
Gene-editing stocks are a promising investment because the field is steadily advancing in the areas of medicine and biotechnology. Examples include CRISPR and other gene-editing technologies.
All You Need to Know About Intellia Therapeutics (NTLA) Rating Upgrade to Strong Buy
01:02pm, Thursday, 11'th Jul 2024
Intellia Therapeutics (NTLA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 Profitable CRISPR Stocks Earning Analysts' Praise
07:59am, Tuesday, 09'th Jul 2024
CRISPR technology, or Clustered Regularly Interspaced Short Palindromic Repeats, is a revolutionary gene-editing tool that allows scientists to make precise modifications to the DNA of living organism
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
07:00am, Tuesday, 09'th Jul 2024
Artificial intelligence stocks will be the choice of growth-oriented investors for years to come. But if you're a buy-and-hold investor with above-average patience, this is a time to look for underval
The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger
05:56am, Tuesday, 09'th Jul 2024
Intellia Therapeutics makes gene editing therapies. Some of those therapies could theoretically cure certain patients.
OAKDALE, Minn.--(BUSINESS WIRE)--BlueAllele® Corporation, a biotechnology company focused on advancing transformational gene editing technologies, filed a patent infringement lawsuit against Intellia
The 3 Best Gene Editing Stocks to Buy in July 2024
09:00am, Monday, 08'th Jul 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. With the technology, we can fix faulty genes, or replace them with healthier gene
3 Pharma Stocks Already Ushering in the Next Biotech Boom
06:00am, Monday, 08'th Jul 2024
Let's get down to it: why should investors consider pharma stocks? Primarily, it comes down to the permanence of the underlying narrative.
The 3 Best Biotech Stocks to Buy in July 2024
02:14pm, Friday, 05'th Jul 2024
Investing in biotech can be pretty unpredictable. Biotech stocks are highly volatile, and picking carefully can be the difference between losing all your capital and making unimaginable profits.
